血浆p-tau217与p-tau181在阿尔茨海默病和额颞叶变性中的诊断性能
这项回顾性多队列诊断性能研究分析了593名参与者,比较血浆p-tau217和p-tau181在区分阿尔茨海默病综合征与额颞叶变性综合征等方面的诊断价值。两者均表现出色,但p-tau217在鉴别阿尔茨海默病与额颞叶变性、指示淀粉样蛋白PET阳性及与tau-PET信号相关性上略优。
要点
- 血浆p-tau217和p-tau181对区分阿尔茨海默病综合征与认知未受损者具有高诊断准确性。
- p-tau217在鉴别阿尔茨海默病综合征与额颞叶变性综合征方面优于p-tau181。
- 两者均可作为识别潜在淀粉样蛋白和tau病理的筛查工具,但需在独立队列中验证。
核心结论
- 血浆p-tau217和p-tau181在区分阿尔茨海默病综合征与其他神经退行性疾病方面均具有极好的诊断性能。
- 有证据支持p-tau217在阿尔茨海默病综合征与额颞叶变性综合征的鉴别诊断、指示淀粉样蛋白PET阳性以及与tau-PET信号相关性方面优于p-tau181。
研究设计与样本
- 回顾性多队列诊断性能研究,分析了来自UCSF记忆与衰老中心和ARTFL联盟的593名参与者(UCSF 443名,ARTFL 150名),平均年龄64岁(SD 13),女性294名(50%)。
- 参与者年龄18-99岁,包括认知未受损者、轻度认知障碍患者、阿尔茨海默病综合征患者和额颞叶变性综合征患者。
- 使用基于电化学发光的检测方法测量血浆p-tau181和p-tau217,并以临床诊断、神经病理发现、淀粉样蛋白PET和tau-PET作为金标准,采用ROC分析和DeLong检验比较AUC。
临床怎么用
- 血浆p-tau217和p-tau181可作为筛查工具,帮助识别具有潜在淀粉样蛋白和阿尔茨海默病tau病理的个体。
- 在需要鉴别阿尔茨海默病综合征与额颞叶变性综合征时,p-tau217可能提供更优的鉴别价值。
局限性
- 结论需在独立、多样且更年长的队列中重复验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma tau phosphorylated at threonine 217 (p-tau217) and plasma tau phosphorylated at threonine 181 (p-tau181) are associated with Alzheimer's disease tau pathology. We compared the diagnostic value of both biomarkers in cognitively unimpaired participants and patients with a clinical diagnosis of mild cognitive impairment, Alzheimer's disease syndromes, or frontotemporal lobar degeneration (FTLD) syndromes. METHODS: In this retrospective multicohort diagnostic performance study, we analysed plasma samples, obtained from patients aged 18-99 years old who had been diagnosed with Alzheimer's disease syndromes (Alzheimer's disease dementia, logopenic variant primary progressive aphasia, or posterior cortical atrophy), FTLD syndromes (corticobasal syndrome, progressive supranuclear palsy, behavioural variant frontotemporal dementia, non-fluent variant primary progressive aphasia, or semantic variant primary progressive aphasia), or mild cognitive impairment; the participants were from the University of California San Francisco (UCSF) Memory and Aging Center, San Francisco, CA, USA, and the Advancing Research and Treatment for Frontotemporal Lobar Degeneration Consortium (ARTFL; 17 sites in the USA and two in Canada). Participants from both cohorts were carefully characterised, including assessments of CSF p-tau181, amyloid-PET or tau-PET (or both), and clinical and cognitive evaluations. Plasma p-tau181 and p-tau217 were measured using electrochemiluminescence-based assays, which differed only in the biotinylated antibody epitope specificity. Receiver operating characteristic analyses were used to determine diagnostic accuracy of both plasma markers using clinical diagnosis, neuropathological findings, and amyloid-PET and tau-PET measures as gold standards. Difference between two area under the curve (AUC) analyses were tested with the Delong test. FINDINGS: Data were collected from 593 participants (443 from UCSF and 150 from ARTFL, mean age 64 years [SD 13], 294 [50%] women) between July 1 and Nov 30, 2020. Plasma p-tau217 and p-tau181 were correlated (r=0·90, p<0·0001). Both p-tau217 and p-tau181 concentrations were increased in people with Alzheimer's disease syndromes (n=75, mean age 65 years [SD 10]) relative to cognitively unimpaired controls (n=118, mean age 61 years [SD 18]; AUC=0·98 [95% CI 0·95-1·00] for p-tau217, AUC=0·97 [0·94-0·99] for p-tau181; pdiff=0·31) and in pathology-confirmed Alzheimer's disease (n=15, mean age 73 years [SD 12]) versus pathologically confirmed FTLD (n=68, mean age 67 years [SD 8]; AUC=0·96 [0·92-1·00] for p-tau217, AUC=0·91 [0·82-1·00] for p-tau181; pdiff=0·22). P-tau217 outperformed p-tau181 in differentiating patients with Alzheimer's disease syndromes (n=75) from those with FTLD syndromes (n=274, mean age 67 years [SD 9]; AUC=0·93 [0·91-0·96] for p-tau217, AUC=0·91 [0·88-0·94] for p-tau181; pdiff=0·01). P-tau217 was a stronger indicator of amyloid-PET positivity (n=146, AUC=0·91 [0·88-0·94]) than was p-tau181 (n=214, AUC=0·89 [0·86-0·93]; pdiff=0·049). Tau-PET binding in the temporal cortex was more strongly associated with p-tau217 than p-tau181 (r=0·80 vs r=0·72; pdiff<0·0001, n=230). INTERPRETATION: Both p-tau217 and p-tau181 had excellent diagnostic performance for differentiating patients with Alzheimer's disease syndromes from other neurodegenerative disorders. There was some evidence in favour of p-tau217 compared with p-tau181 for differential diagnosis of Alzheimer's disease syndromes versus FTLD syndromes, as an indication of amyloid-PET-positivity, and for stronger correlations with tau-PET signal. Pending replication in independent, diverse, and older cohorts, plasma p-tau217 and p-tau181 could be useful screening tools to identify individuals with underlying amyloid and Alzheimer's disease tau pathology. FUNDING: US National Institutes of Health, State of California Department of Health Services, Rainwater Charitable Foundation, Michael J Fox foundation, Association for Frontotemporal Degeneration, Alzheimer's Association.
引用
- Thijssen EH, La Joie R, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 2021. PMID: 34418401. doi:10.1016/S1474-4422(21)00214-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。